Team:LMU-TUM Munich/Integrated Practices

Integrated Practices

After speaking with medical doctors and medical students as well as experts in the field of drug design, we found that some of them were concerned about the immunogenicity of non-self proteins with respect to synthetic implants, which we took to apply to the protein components of our bioprinting approach as well. Thus, we implemented the "Linker Chemistry" section, which, among other aspects, addresses how to dissolve the protein matrix employed in our bioprinting system at a given point in time. In addition, we considered and assessed different types of kill-switches to eliminate the printed cell population if necessary, and in this context implemented a simple and effective prodrug-based system.